| 1 |
34328253 | In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. | 2021 Nov |
3 |
| 2 |
34909672 | Pharmacokinetic drug interactions of integrase strand transfer inhibitors. | 2021 |
1 |
| 3 |
32011683 | Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. | 2020 May 1 |
2 |
| 4 |
28915895 | Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. | 2017 Sep 16 |
4 |
| 5 |
26898568 | Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. | 2016 Jun |
2 |
| 6 |
25733917 | The role of dolutegravir in the management of HIV infection. | 2015 |
1 |
| 7 |
25845873 | Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. | 2015 |
1 |
| 8 |
25858605 | [Mechanisms of action, pharmacology and interactions of dolutegravir]. | 2015 Mar |
1 |
| 9 |
24096683 | Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. | 2014 Jan |
2 |
| 10 |
23824675 | Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. | 2013 Nov |
1 |